Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Akebia Therapeutics Inc’s stock clocked out at $2.81, down -3.77% from its previous closing price of $2.92. In other words, the price has decreased by -$3.77 from its previous closing price. On the day, 4.8 million shares were traded.
Ratios:
To gain a deeper understanding of AKBA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.02 and its Current Ratio is at 2.23. In the meantime, Its Debt-to-Equity ratio is 8.39 whereas as Long-Term Debt/Eq ratio is at 7.41.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on April 28, 2025, initiated with a Outperform rating and assigned the stock a target price of $7.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when Butler John P. sold 46,409 shares for $1.83 per share. The transaction valued at 84,928 led to the insider holds 2,557,921 shares of the business.
Burke Steven Keith sold 7,144 shares of AKBA for $13,074 on Mar 03 ’25. The SVP, Chief Medical Officer now owns 809,090 shares after completing the transaction at $1.83 per share. On Mar 03 ’25, another insider, Burke Steven Keith, who serves as the Officer of the company, bought 7,144 shares for $1.83 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.99 while its Price-to-Book (P/B) ratio in mrq is 29.91.
Stock Price History:
Over the past 52 weeks, AKBA has reached a high of $2.97, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 28.31%, while the 200-Day Moving Average is calculated to be 52.35%.
Shares Statistics:
A total of 261.64M shares are outstanding, with a floating share count of 251.86M. Insiders hold about 4.10% of the company’s shares, while institutions hold 36.58% stake in the company.
Earnings Estimates
The stock of Akebia Therapeutics Inc (AKBA) is currently being evaluated by 1.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.03 and low estimates of -$0.03.
Analysts are recommending an EPS of between -$0.09 and -$0.09 for the fiscal current year, implying an average EPS of -$0.09. EPS for the following year is $0.42, with 1.0 analysts recommending between $0.42 and $0.42.
Revenue Estimates
In the current quarter, 4 analysts expect revenue to total $47.3M. It ranges from a high estimate of $50.8M to a low estimate of $45.8M. As of the current estimate, Akebia Therapeutics Inc’s year-ago sales were $43.65MFor the next quarter, 4 analysts are estimating revenue of $44.67M. There is a high estimate of $48.89M for the next quarter, whereas the lowest estimate is $38.7M.
A total of 4 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $206.14M, while the lowest revenue estimate was $184.4M, resulting in an average revenue estimate of $198.61M. In the same quarter a year ago, actual revenue was $160.18MBased on 4 analysts’ estimates, the company’s revenue will be $290.86M in the next fiscal year. The high estimate is $395.54M and the low estimate is $209.4M.
